Cargando…

Are ketogenic diets promising for Alzheimer’s disease? A translational review

BACKGROUND: Brain amyloid deposition and neurofibrillary tangles in Alzheimer’s disease (AD) are associated with complex neuroinflammatory reactions such as microglial activation and cytokine production. Glucose metabolism is closely related to neuroinflammation. Ketogenic diets (KDs) include a high...

Descripción completa

Detalles Bibliográficos
Autores principales: Lilamand, Matthieu, Porte, Baptiste, Cognat, Emmanuel, Hugon, Jacques, Mouton-Liger, François, Paquet, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158135/
https://www.ncbi.nlm.nih.gov/pubmed/32290868
http://dx.doi.org/10.1186/s13195-020-00615-4
_version_ 1783522477627932672
author Lilamand, Matthieu
Porte, Baptiste
Cognat, Emmanuel
Hugon, Jacques
Mouton-Liger, François
Paquet, Claire
author_facet Lilamand, Matthieu
Porte, Baptiste
Cognat, Emmanuel
Hugon, Jacques
Mouton-Liger, François
Paquet, Claire
author_sort Lilamand, Matthieu
collection PubMed
description BACKGROUND: Brain amyloid deposition and neurofibrillary tangles in Alzheimer’s disease (AD) are associated with complex neuroinflammatory reactions such as microglial activation and cytokine production. Glucose metabolism is closely related to neuroinflammation. Ketogenic diets (KDs) include a high amount of fat, low carbohydrate and medium-chain triglyceride (MCT) intake. KDs lead to the production of ketone bodies to fuel the brain, in the absence of glucose. These nutritional interventions are validated treatments of pharmacoresistant epilepsy, consequently leading to a better intellectual development in epileptic children. In neurodegenerative diseases and cognitive decline, potential benefits of KD were previously pointed out, but the published evidence remains scarce. The main objective of this review was to critically examine the evidence regarding KD or MCT intake effects both in AD and ageing animal models and in humans. MAIN BODY: We conducted a review based on a systematic search of interventional trials published from January 2000 to March 2019 found on MEDLINE and Cochrane databases. Overall, 11 animal and 11 human studies were included in the present review. In preclinical studies, this review revealed an improvement of cognition and motor function in AD mouse model and ageing animals. However, the KD and ketone supplementation were also associated with significant weight loss. In human studies, most of the published articles showed a significant improvement of cognitive outcomes (global cognition, memory and executive functions) with ketone supplementation or KD, regardless of the severity of cognitive impairments previously detected. Both interventions seemed acceptable and efficient to achieve ketosis. CONCLUSION: The KD or MCT intake might be promising ways to alter cognitive symptoms in AD, especially at the prodromal stage of the disease. The need for efficient disease-modifying strategies suggests to pursue further KD interventional studies to assess the efficacy, the adherence to this diet and the potential adverse effects of these nutritional approaches.
format Online
Article
Text
id pubmed-7158135
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71581352020-04-21 Are ketogenic diets promising for Alzheimer’s disease? A translational review Lilamand, Matthieu Porte, Baptiste Cognat, Emmanuel Hugon, Jacques Mouton-Liger, François Paquet, Claire Alzheimers Res Ther Review BACKGROUND: Brain amyloid deposition and neurofibrillary tangles in Alzheimer’s disease (AD) are associated with complex neuroinflammatory reactions such as microglial activation and cytokine production. Glucose metabolism is closely related to neuroinflammation. Ketogenic diets (KDs) include a high amount of fat, low carbohydrate and medium-chain triglyceride (MCT) intake. KDs lead to the production of ketone bodies to fuel the brain, in the absence of glucose. These nutritional interventions are validated treatments of pharmacoresistant epilepsy, consequently leading to a better intellectual development in epileptic children. In neurodegenerative diseases and cognitive decline, potential benefits of KD were previously pointed out, but the published evidence remains scarce. The main objective of this review was to critically examine the evidence regarding KD or MCT intake effects both in AD and ageing animal models and in humans. MAIN BODY: We conducted a review based on a systematic search of interventional trials published from January 2000 to March 2019 found on MEDLINE and Cochrane databases. Overall, 11 animal and 11 human studies were included in the present review. In preclinical studies, this review revealed an improvement of cognition and motor function in AD mouse model and ageing animals. However, the KD and ketone supplementation were also associated with significant weight loss. In human studies, most of the published articles showed a significant improvement of cognitive outcomes (global cognition, memory and executive functions) with ketone supplementation or KD, regardless of the severity of cognitive impairments previously detected. Both interventions seemed acceptable and efficient to achieve ketosis. CONCLUSION: The KD or MCT intake might be promising ways to alter cognitive symptoms in AD, especially at the prodromal stage of the disease. The need for efficient disease-modifying strategies suggests to pursue further KD interventional studies to assess the efficacy, the adherence to this diet and the potential adverse effects of these nutritional approaches. BioMed Central 2020-04-14 /pmc/articles/PMC7158135/ /pubmed/32290868 http://dx.doi.org/10.1186/s13195-020-00615-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Lilamand, Matthieu
Porte, Baptiste
Cognat, Emmanuel
Hugon, Jacques
Mouton-Liger, François
Paquet, Claire
Are ketogenic diets promising for Alzheimer’s disease? A translational review
title Are ketogenic diets promising for Alzheimer’s disease? A translational review
title_full Are ketogenic diets promising for Alzheimer’s disease? A translational review
title_fullStr Are ketogenic diets promising for Alzheimer’s disease? A translational review
title_full_unstemmed Are ketogenic diets promising for Alzheimer’s disease? A translational review
title_short Are ketogenic diets promising for Alzheimer’s disease? A translational review
title_sort are ketogenic diets promising for alzheimer’s disease? a translational review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158135/
https://www.ncbi.nlm.nih.gov/pubmed/32290868
http://dx.doi.org/10.1186/s13195-020-00615-4
work_keys_str_mv AT lilamandmatthieu areketogenicdietspromisingforalzheimersdiseaseatranslationalreview
AT portebaptiste areketogenicdietspromisingforalzheimersdiseaseatranslationalreview
AT cognatemmanuel areketogenicdietspromisingforalzheimersdiseaseatranslationalreview
AT hugonjacques areketogenicdietspromisingforalzheimersdiseaseatranslationalreview
AT moutonligerfrancois areketogenicdietspromisingforalzheimersdiseaseatranslationalreview
AT paquetclaire areketogenicdietspromisingforalzheimersdiseaseatranslationalreview